Eli Lilly announced a plan for people with diabetes to access price discounts on insulin via mobile and web platforms. The Endocrine Society praised the company’s action, which addresses the call for entities in the supply chain to keep insulin accessible to those who need it, according to an Endocrine Society press release. Lilly partnered with the pharmacy benefit management organization Express Scripts to use its platform Blink Health to offer the discounts. Mike Mason, vice president of Lilly Diabetes, said in a company press release that,  “We understand the burden people face when paying full price for insulin….This platform will effectively allow Lilly to lower our insulin retail prices for users of this platform while not affecting the reimbursement system for other people living with diabetes.” Blink Health will allow patients who pay full price for Lilly insulins, such as those without insurance or those in the deductible phase of a high-deductible insurance plan, to save up to 40%. The plan went into effect January 1, 2017. Also, Novo Nordisk said it would limit price increases for insulin and was open to collaborations to address the rising prices.